Contents:

1 Executive Summary 2 Cancer Highlights 3 Methodology 4 Table of Contents 4.1 List of boxes 4.2 List of tables 4.3 Appendices 5 Introduction 5.1 Current Treatment Strategies 5.2 Disease Definition 5.3 Etiology & Pathophysiology 5.4 Prognosis 5.5 Epidemiology 6 Progress in current treatment strategies 6.1 Improvements adding microtubule inhibitor 6.2 Improvement of disease related symptoms in elderly patients 6.3 Toxicity profile favored 6.4 A new formula 6.5 Monotherapy? 6.6 Failed to demonstrate a survival advantage 6.7 Reduction in mortality risk 7 Key Drug Strategies in Lung Cancer 7.1 Apoptosis 7.2 Antiangiogenesis and Antivascular Agents 7.2.1 EGFR and VEGFR as target 7.3 Immunotherapy 8 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline 8.1 Grade 4 adverse events 8.2 No new remarks 8.3 No significant effect on overall survival 8.4 Bristol Myers Squibb entered into an agreement 8.5 Many uncertainties remain. 8.6 Development terminated 8.7 Continuing Enrollment 8.8 Apoptotic inducer 8.9 Fully-human monoclonal antibody 8.10 Eagerly awaiting data 8.11 Mutations and response 8.12 Statistically and clinically significant survival advantage 8.13 Anti-idiotypic monoclonal antibody 8.14 Shift in the development focus 8.15 Sensitizer 8.16 Treatment in earlier-stage cancer could be more effective 8.17 Discontinued radiosensitizer 8.18 Improvement in chemoradiotherapy 8.19 Progress on HDAC inhibitor 8.20 Progress Analysis Carboxyamidotriazole 8.21 Chemotherapy naïve subjects 9 Disclaimer 9.1 Liability 9.2 Completeness 10 Appendix 1. Treatment Guide Lines* 10.1 References 11 Appendix 2: Selected Company Profiles 11.1 Abgenix 11.2 Aphton 11.3 AstraZeneca 11.4 Bristol-Myers Squibb 11.5 Eli Lilly 11.6 Genentech 11.7 Genta. 11.8 GlaxoSmithKline 11.9 ImClone 11.10 ISIS Pharmaceuticals 11.11 Ligand Pharmaceuticals 11.12 OSI Pharmaceuticals 11.13 Pfizer 11.14 Pharmacyclics 11.15 Sanofi- Aventis 11.16 Telik 12 Appendix 3 Progress profiles on approved drugs 12.1 Docetaxel 12.2 Vinorelbine 12.3 Gemcitabine 12.4 Paclitaxel 12.5 Pemetrexed 12.6 Gefitinib 12.7 Erlotinib 13 Drug Index 14 Company Index 4.1 List of boxes Box 1: Scientific Data on Docetaxel Box 2: Quick Facts – Vinorelbine Box 3: Scientific Data on Vinorelbine Box 4: Quick Facts – Gemcitabine Box 5: Scientific Data on gemcitabine Box 6: Scientific Data on Pemetrexed Box 7: Quick Facts – pemetrexed Box 8: Quick Facts – Gefitinib Box 9: Scientific Data on Gefitinib Box 10: Quick Facts – Erlotinib 4.2 List of tables Table 1: Chemotherapeutic drugs for treatment of NSCLC Table 2. Near Term Approved Drugs for the Treatment of NSCLC Table 3: Chemotherapy Drugs off Patent Table 4 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways. Table 5 VTA agents under development Table 6 EGFR or VEGFR inhibitors Table 7: FMS-like tyrosine kinases and their Synonyms Table 8: Fms-related Tyrosine Kinase Targets in Development Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer Table 10 Cancer immunotherapy strategies Table 11 Recently presented studies Lapatinib Table 12 Recently presented studies ZD-6474 Table 13 Recently presented studies vinflunine Table 14 Recently presented studies Panitumumab Table 15 Recently presented studies Genasense Table 16 Recently presented studies cetuximab Table 17 Recently presented studies bevacizumab Table 18 Recently presented studies bexarotene1 Table 19 Recently presented studies Xcytrin 4.3 Appendices 10 Appendix 1. Treatment Guide Lines* 11 Appendix 2: Selected Company Profiles 12 Appendix 3 Progress profiles on approved drugs

Companies Mentioned

- Abgenix - Aphton - AstraZeneca - Bristol-Myers Squibb - Cell Pathways - Eli Lilly - Genentech - Genta - GlaxoSmithKline - ImClone - ISIS Pharmaceuticals - Ligand Pharmaceuticals - OSI Pharmaceuticals - Pfizer - Pharmacyclics - Sanofi-Aventis - Telik